552 related articles for article (PubMed ID: 15907389)
1. [Therapeutic monoclonal antibodies: a little history, a lot of engineering, and... some clinical successes].
Siberil S; Dutertre CA; Boix C; Teillaud JL
Transfus Clin Biol; 2005 Jun; 12(2):114-22. PubMed ID: 15907389
[TBL] [Abstract][Full Text] [Related]
2. Historical development of monoclonal antibody therapeutics.
Nissim A; Chernajovsky Y
Handb Exp Pharmacol; 2008; (181):3-18. PubMed ID: 18071939
[TBL] [Abstract][Full Text] [Related]
3. Engineering of monoclonal antibodies and antibody-based fusion proteins: successes and challenges.
Teillaud JL
Expert Opin Biol Ther; 2005 Sep; 5 Suppl 1():S15-27. PubMed ID: 16187937
[TBL] [Abstract][Full Text] [Related]
4. Three decades of human monoclonal antibodies: past, present and future developments.
Steinitz M
Hum Antibodies; 2009; 18(1-2):1-10. PubMed ID: 19478393
[TBL] [Abstract][Full Text] [Related]
5. Single-chain antibodies as diagnostic tools and therapeutic agents.
Hagemeyer CE; von Zur Muhlen C; von Elverfeldt D; Peter K
Thromb Haemost; 2009 Jun; 101(6):1012-9. PubMed ID: 19492141
[TBL] [Abstract][Full Text] [Related]
6. Target therapy of cancer: implementation of monoclonal antibodies and nanobodies.
Majidi J; Barar J; Baradaran B; Abdolalizadeh J; Omidi Y
Hum Antibodies; 2009; 18(3):81-100. PubMed ID: 19729803
[TBL] [Abstract][Full Text] [Related]
7. Engineering of stable bispecific antibodies targeting IL-17A and IL-23.
Mabry R; Lewis KE; Moore M; McKernan PA; Bukowski TR; Bontadelli K; Brender T; Okada S; Lum K; West J; Kuijper JL; Ardourel D; Franke S; Lockwood L; Vu T; Frank A; Appleby MW; Wolf A; Reardon B; Hamacher NB; Stevens B; Lewis P; Lewis KB; Gilbertson DG; Lantry M; Julien SH; Ostrander C; Chan C; Byrnes-Blake K; Brody J; Presnell S; Meengs B; Levin SD; Snavely M
Protein Eng Des Sel; 2010 Mar; 23(3):115-27. PubMed ID: 20022918
[TBL] [Abstract][Full Text] [Related]
8. Recent advances in the generation of bispecific antibodies for tumor immunotherapy.
Kipriyanov SM; Le Gall F
Curr Opin Drug Discov Devel; 2004 Mar; 7(2):233-42. PubMed ID: 15603258
[TBL] [Abstract][Full Text] [Related]
9. Engineered antibodies take center stage.
Huston JS; George AJ
Hum Antibodies; 2001; 10(3-4):127-42. PubMed ID: 11847424
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal and recombinant antibodies, 30 years after ..
Laffly E; Sodoyer R
Hum Antibodies; 2005; 14(1-2):33-55. PubMed ID: 16424599
[TBL] [Abstract][Full Text] [Related]
11. Fluorescent cocaine probes: a tool for the selection and engineering of therapeutic antibodies.
Meijler MM; Kaufmann GF; Qi L; Mee JM; Coyle AR; Moss JA; Wirsching P; Matsushita M; Janda KD
J Am Chem Soc; 2005 Mar; 127(8):2477-84. PubMed ID: 15725002
[TBL] [Abstract][Full Text] [Related]
12. Multivalency: the hallmark of antibodies used for optimization of tumor targeting by design.
Deyev SM; Lebedenko EN
Bioessays; 2008 Sep; 30(9):904-18. PubMed ID: 18693269
[TBL] [Abstract][Full Text] [Related]
13. [Therapeutic antibodies and related products: choosing the right structure for success].
Beck A; Wagner-Rousset E; Wurch T; Corvaia N
Med Sci (Paris); 2009 Dec; 25(12):1024-32. PubMed ID: 20035674
[TBL] [Abstract][Full Text] [Related]
14. Selection, design, and engineering of therapeutic antibodies.
Presta LG
J Allergy Clin Immunol; 2005 Oct; 116(4):731-6; quiz 737. PubMed ID: 16210043
[TBL] [Abstract][Full Text] [Related]
15. Bispecific antibodies for cancer therapy.
Chames P; Baty D
Curr Opin Drug Discov Devel; 2009 Mar; 12(2):276-83. PubMed ID: 19333873
[TBL] [Abstract][Full Text] [Related]
16. A novel CD19-directed recombinant bispecific antibody derivative with enhanced immune effector functions for human leukemic cells.
Kellner C; Bruenke J; Stieglmaier J; Schwemmlein M; Schwenkert M; Singer H; Mentz K; Peipp M; Lang P; Oduncu F; Stockmeyer B; Fey GH
J Immunother; 2008; 31(9):871-84. PubMed ID: 18833000
[TBL] [Abstract][Full Text] [Related]
17. [Monoclonals antibodies: a recent and major therapeutic advance].
Paintaud G; Lejarre F; Ternant D; Goupille P; Watier H
Therapie; 2009; 64(1):1-7. PubMed ID: 19463247
[TBL] [Abstract][Full Text] [Related]
18. Humanized antibodies as potential drugs for therapeutic use.
Merluzzi S; Figini M; Colombatti A; Canevari S; Pucillo C
Adv Clin Path; 2000 Apr; 4(2):77-85. PubMed ID: 11080787
[TBL] [Abstract][Full Text] [Related]
19. Engineered antibodies.
Hudson PJ; Souriau C
Nat Med; 2003 Jan; 9(1):129-34. PubMed ID: 12514726
[No Abstract] [Full Text] [Related]
20. Engineering therapeutic monoclonal antibodies.
Liu XY; Pop LM; Vitetta ES
Immunol Rev; 2008 Apr; 222():9-27. PubMed ID: 18363992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
